HCPCS Level II · Drugs administered other than oral method
J1725Injection, hydroxyprogesterone caproate, 1 mg
Terminated 12/31/2017
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1725
J1725 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, hydroxyprogesterone caproate, 1 mg.
It was added to HCPCS effective 01/01/2012, and its current record took effect 01/01/2018.
It was terminated on 12/31/2017 and can't be billed for later dates of service.
Its Medicare coverage code is "I", meaning it is not payable by Medicare (another code or method is used).
Details
- Short description
- Hydroxyprogesterone caproate
- Date added
- 01/01/2012
- Action effective
- 01/01/2018
- Termination date
- 12/31/2017
- BETOS
- O1E
Related J17xx codes
- J1700Injection, hydrocortisone acetate, up to 25 mg
- J1720Injection, hydrocortisone sodium succinate, up to 100 mg
- J1726Injection, hydroxyprogesterone caproate, (makena), 10 mg
- J1729Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- J1730Injection, diazoxide, up to 300 mg
- J1736Injection, meloxicam (delova), 1 mg
- J1737Injection, meloxicam (azurity), 1 mg
- J1738Injection, meloxicam, 1 mg
- J1740Injection, ibandronate sodium, 1 mg
- J1741Injection, ibuprofen, 100 mg
- J1742Injection, ibutilide fumarate, 1 mg
- J1743Injection, idursulfase, 1 mg
Common questions about J1725
Is HCPCS J1725 still valid?
- No. J1725 was terminated on 12/31/2017.
Does Medicare cover J1725?
- Its coverage code is "I": it is not payable by Medicare (another code or method is used). Check the local coverage determination for your region.